Arvinas, Inc. (ARVN) News
Filter ARVN News Items
ARVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARVN News Highlights
- ARVN's 30 day story count now stands at 7.
- Over the past 22 days, the trend for ARVN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ARVN are PFE, PRE and ADD.
Latest ARVN News From Around the Web
Below are the latest news stories about ARVINAS INC that investors may wish to consider to help them evaluate ARVN as an investment opportunity.
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Poised to Perform in 2024In just a few days, we’ll celebrate a new year, with a short break to watch the Old Year out and the New Year in, ending a marathon run of holidays that started with Thanksgiving. It’s a time to gather with family, catch our breath, and get ready to plunge back into the day-to-day business of ordinary life. And for stock traders, that means finding the best stocks to add to a profitable investment portfolio. The markets put up a massive wall of raw data, all the information generated by thousand |
Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to TradeThe consensus price target hints at a 42.1% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
12 Most Promising Cancer Stocks According to AnalystsIn this piece, we will take a look at the 12 most promising cancer stocks according to analysts. If you want to skip our overview of the latest trends in the cancer treatment sector, then you can take a look at the 5 Most Promising Cancer Stocks According to Analysts. The advent of technology and […] |
Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year?Here is how Arvinas, Inc. (ARVN) and Novo Nordisk (NVO) have performed compared to their sector so far this year. |
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer StudyInterim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients. |
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development ProgramNEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc. (NYSE: PFE) to discuss vepdegestrant (ARV-471) data presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) as well as plans to expand the vepdegestrant development program. Investor Call & W |
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the potential of vepdegestrant in combination with palbociclib (IBRANCE®) – – Tolerability generally consistent with the profile of palbociclib and what has been observed in other clinical trials of vepdegestrant– – Pending additional data and agreement with regulatory authorities, Arvinas and Pfizer pla |
Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 145.5% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant is a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrog |
Arvinas Announces Oversubscribed $350 Million Private PlacementNEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 12,963,542 shares of common stock at a price of $21.36 per share and, in lieu of common stock, pre-funded warrants to purchase up to 3,422,380 shares of common stock at a |